Literature DB >> 31004425

Scopolamine Toxicity in an Elderly Patient.

Kayla M Knuf1, Francis M Spaulding1, Gregory J Stevens1.   

Abstract

We present a case of a 66-year-old female who was to undergo a scheduled operation and placed on our institution's ERAS (Enhanced Recovery After Surgery) protocol. The intraoperative course was unremarkable. The patient developed delayed emergence in the Post-Anesthesia Care Unit. On physical exam, the patient was noted to have a transdermal scopolamine patch adjacent to an area of skin breakdown. She also displayed signs of central anti-cholinergic toxicity including mydriasis and tachycardia. Following removal of the scopolamine patch and administration of physostigmine, her mental status returned to baseline. This interesting case highlights the importance of considering patient specific factors such as age when implementing ERAS protocols perioperatively. It also demonstrates the risks associated with scopolamine and the importance of risk/benefit analysis prior to administration. © Association of Military Surgeons of the United States 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Central Anticholinergic Syndrome; Enhanced Recovery After Surgery; Geriatric Medicine; Perioperative Medicine

Year:  2019        PMID: 31004425     DOI: 10.1093/milmed/usz086

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  2 in total

1.  Penehyclidine for prevention of postoperative nausea and vomiting following bimaxillary orthognathic surgery: a randomized, double-blind, controlled trial.

Authors:  Li-Kuan Wang; Tong Cheng; Xu-Dong Yang; Guo-Li Xiong; Nan Li; Dong-Xin Wang
Journal:  J Anesth       Date:  2021-11-05       Impact factor: 2.078

2.  Determination of Scopolamine Distribution in Plasma and Brain by LC-MS/MS in Rats.

Authors:  Juan Chen; Anjing Lu; Daopeng Tan; Qianru Zhang; Yanliu Lu; Lin Qin; Yuqi He
Journal:  Int J Anal Chem       Date:  2022-09-30       Impact factor: 1.698

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.